MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymgmr.2026.101324

Медицинская библиотека · Molecular genetics and metabolism reports · 2026

A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics.

Zhang Lihui, Luo Xue-Qun, Fang Yongjun, Zhang Fengkui, Meng Yan, Luo Xiaoping, Zhang Liansheng, Qiu Zhengqing, Ge Xiao, Botha Jaco, Zhan Jenny, Wang Tianyou

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Velaglucerase alfa is approved in China for treating type 1 Gaucher disease (GD1), but data on its use in Chinese pediatric and adult patients are limited. This study evaluated the safety, efficacy, and pharmacokinetics of velaglucerase alfa in Chinese patients with GD1.

METHODS

This was a phase IIIb, multicenter, open-label, single-arm, 53-week study (NCT05529992). Patients received intravenous velaglucerase alfa (60 U/kg) every 2 weeks. The primary endpoint was the incidence of serious treatment-emergent adverse events (TEAEs). Secondary endpoints evaluated safety (incidence of TEAEs), efficacy (changes in hemoglobin concentrations, platelet counts, liver and spleen volumes [as percent of body weight, % BW]), and quality of life (QoL).

RESULTS

Twenty patients were enrolled (treatment-naïve, n = 16; previously treated, n = 4). Four patients experienced 4 serious TEAEs requiring hospitalization; none were treatment-related. Overall, 19 of 20 patients experienced 104 TEAEs, of which 9 were treatment-related (8.7%; all mild). No TEAEs or deaths led to discontinuation of treatment. Mean (SD) improvements in hemoglobin concentrations (baseline, 10.5 g/dL [2.2]; change, +2.3 g/dL [1.3]; +25.5%), platelet counts (baseline, 59.9 × 109/L [23.4]; change, +42.1 × 109/L [27.7]; +82.3%), normalized spleen (baseline, 5.2% BW [2.6]; change, -3.1% BW [1.6]; -58.4%), and liver volume (baseline, 4.6% BW [1.3]; change, -1.1% BW [0.9]; -21.5%) were observed through Week 53. Nineteen of 20 (95.0%) patients reported improved QoL.

CONCLUSIONS

Velaglucerase alfa was well-tolerated in Chinese patients with GD1, with no new safety signals, and resulted in improved hemoglobin and platelet levels, as well as liver and spleen volumes.

Для цитирования: Zhang Lihui, Luo Xue-Qun, Fang Yongjun, Zhang Fengkui, Meng Yan, Luo Xiaoping, Zhang Liansheng, Qiu Zhengqing, Ge Xiao, Botha Jaco, Zhan Jenny, Wang Tianyou. A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics.. Molecular genetics and metabolism reports. 2026. DOI: 10.1016/j.ymgmr.2026.101324.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.